Bio-Inspired siRNA Hybrid Vesicles for Targeted Liver Fibrosis Therapy 

HyPSomes are biomimetic hybrid vesicles formed by fusing activated liver-cell (LX-2) membranes with siRNA-loaded synthetic vesicles. Carrying the natural recognition proteins of hepatic stellate cells, they home to activated cells in the fibrotic liver, enhance intracellular siRNA delivery, and silence fibrosis-driving genes — a targeted gene-therapy strategy for liver fibrosis.

Biomimetic hybrid nanocarrier engineering for liver-targeted siRNA delivery and anti-inflammatory therapy 

This nanocarrier integrates three complementary components — hepatocyte-derived membrane vesicles, polymersomes (PSomes), and mesoporous silica nanoparticles (MSNs) — for liver-targeted siTNF-α delivery. The membrane provides liver-cell recognition, the polymersome adds vesicular stability, and the silica core loads and protects the siRNA, together suppressing TNF-α expression and relieving hepatic inflammation.

Biomimetic LX-2 Cell Membrane–Polymersome Hybrid Nanoplatform for Targeted siRNA Delivery to Hepatic Stellate Cells 

Nano-extruding LX-2 cell membranes together with mPEG-b-PLA polymersomes produces a single biomimetic hybrid vesicle for siRNA delivery. The polymersome core supplies mechanical stability and cargo capacity while the LX-2 membrane shell adds homotypic targeting toward hepatic stellate cells, together enabling efficient siRNA loading, improved uptake by activated stellate cells, and enhanced intracellular delivery for anti-fibrotic gene silencing.

Engineering Mesoporous Silica–Liposome–LX-2 Cell Membrane Vesicle Hybrid Nanoparticles for In Vivo Targeted siRNA Delivery in Liver Fibrosis

Hybrid nanoparticles combining a mesoporous silica core, a liposome layer, and an LX-2 cell-membrane coat deliver COL1A1-silencing siRNA to the fibrotic liver. After systemic injection they accumulate in the liver and are taken up by activated hepatic stellate cells, where endosomal escape and RISC-mediated COL1A1 silencing reduce collagen deposition and alleviate liver fibrosis in vivo.